A citation-based method for searching scientific literature

Lingyun Xu, Yansheng Zhao, Zhiqiang Chen, Yujiao Wang, Lin Chen, Shui Wang. Breast Cancer 2015
Times Cited: 15







List of co-cited articles
125 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
Kelly-Anne Phillips, Roger L Milne, Matti A Rookus, Mary B Daly, Antonis C Antoniou, Susan Peock, Debra Frost, Douglas F Easton, Steve Ellis, Michael L Friedlander,[...]. J Clin Oncol 2013
113
40

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Emma Nolan, François Vaillant, Daniel Branstetter, Bhupinder Pal, Göknur Giner, Lachlan Whitehead, Sheau W Lok, Gregory B Mann, Kathy Rohrbach, Li-Ya Huang,[...]. Nat Med 2016
167
33

Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Joanne Kotsopoulos, Tomasz Huzarski, Jacek Gronwald, Christian F Singer, Pal Moller, Henry T Lynch, Susan Armel, Beth Karlan, William D Foulkes, Susan L Neuhausen,[...]. J Natl Cancer Inst 2016
119
33

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Jack Cuzick, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell, John F Forbes. Lancet Oncol 2015
246
26

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. Cancer Prev Res (Phila) 2010
397
26

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Bernard Fisher, Joseph P Costantino, D Lawrence Wickerham, Reena S Cecchini, Walter M Cronin, Andre Robidoux, Therese B Bevers, Maureen T Kavanah, James N Atkins, Richard G Margolese,[...]. J Natl Cancer Inst 2005
849
26

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
B Fisher, J P Costantino, D L Wickerham, C K Redmond, M Kavanah, W M Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins,[...]. J Natl Cancer Inst 1998
26

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.
Jack Cuzick, Ivana Sestak, Bernardo Bonanni, Joseph P Costantino, Steve Cummings, Andrea DeCensi, Mitch Dowsett, John F Forbes, Leslie Ford, Andrea Z LaCroix,[...]. Lancet 2013
279
26


Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.
Aleksandra Jovanovic Poole, Ying Li, Yoon Kim, Suh-Chin J Lin, Wen-Hwa Lee, Eva Y-H P Lee. Science 2006
231
26

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations.
M Bramley, R B Clarke, A Howell, D G R Evans, T Armer, A D Baildam, E Anderson. Br J Cancer 2006
18
26

RANKL/RANK control Brca1 mutation- .
Verena Sigl, Kwadwo Owusu-Boaitey, Purna A Joshi, Anoop Kavirayani, Gerald Wirnsberger, Maria Novatchkova, Ivona Kozieradzki, Daniel Schramek, Nnamdi Edokobi, Jerome Hersl,[...]. Cell Res 2016
93
26

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
26

Risk-reducing mastectomy for the prevention of primary breast cancer.
Nora E Carbine, Liz Lostumbo, Judi Wallace, Henry Ko. Cochrane Database Syst Rev 2018
107
26

Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.
Xiao Li, Ran You, Xinwei Wang, Congxin Liu, Zicheng Xu, Jin Zhou, Bin Yu, Ting Xu, Hongzhou Cai, Qing Zou. Clin Cancer Res 2016
85
26

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Y Miki, J Swensen, D Shattuck-Eidens, P A Futreal, K Harshman, S Tavtigian, Q Liu, C Cochran, L M Bennett, W Ding. Science 1994
26

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. JAMA 2006
20

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Jack Cuzick, John F Forbes, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell. J Natl Cancer Inst 2007
364
20

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
J Cuzick, J Forbes, R Edwards, M Baum, S Cawthorn, A Coates, A Hamed, A Howell, T Powles. Lancet 2002
524
20

The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.
Martin Widschwendter, Adam N Rosenthal, Sue Philpott, Ivana Rizzuto, Lindsay Fraser, Jane Hayward, Maria P Intermaggio, Christopher K Edlund, Susan J Ramus, Simon A Gayther,[...]. Lancet Oncol 2013
80
20

Exemestane for breast-cancer prevention in postmenopausal women.
Paul E Goss, James N Ingle, José E Alés-Martínez, Angela M Cheung, Rowan T Chlebowski, Jean Wactawski-Wende, Anne McTiernan, John Robbins, Karen C Johnson, Lisa W Martin,[...]. N Engl J Med 2011
579
20

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
C Davies, J Godwin, R Gray, M Clarke, D Cutter, S Darby, P McGale, H C Pan, C Taylor, Y C Wang,[...]. Lancet 2011
20

Out-RANKing BRCA1 in Mutation Carriers.
Emma Nolan, Geoffrey J Lindeman, Jane E Visvader. Cancer Res 2017
23
20

Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.
D Gareth R Evans, Sarah L Ingham, Andrew Baildam, Gary L Ross, Fiona Lalloo, Iain Buchan, Anthony Howell. Breast Cancer Res Treat 2013
98
20

Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.
Rowan T Chlebowski, Thomas E Rohan, JoAnn E Manson, Aaron K Aragaki, Andrew Kaunitz, Marcia L Stefanick, Michael S Simon, Karen C Johnson, Jean Wactawski-Wende, Mary J O'Sullivan,[...]. JAMA Oncol 2015
127
20

Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.
Kelly Metcalfe, Shelley Gershman, Parviz Ghadirian, Henry T Lynch, Carrie Snyder, Nadine Tung, Charmaine Kim-Sing, Andrea Eisen, William D Foulkes, Barry Rosen,[...]. BMJ 2014
166
20

Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Jacek Gronwald, Andre Robidoux, Charmaine Kim-Sing, Nadine Tung, Henry T Lynch, William D Foulkes, Siranoush Manoukian, Peter Ainsworth, Susan L Neuhausen, Rochelle Demsky,[...]. Breast Cancer Res Treat 2014
21
20

Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
B A M Heemskerk-Gerritsen, C Seynaeve, C J van Asperen, M G E M Ausems, J M Collée, H C van Doorn, E B Gomez Garcia, C M Kets, F E van Leeuwen, H E J Meijers-Heijboer,[...]. J Natl Cancer Inst 2015
124
20

Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.
Jack Cuzick, Jane Warwick, Elizabeth Pinney, Stephen W Duffy, Simon Cawthorn, Anthony Howell, John F Forbes, Ruth M L Warren. J Natl Cancer Inst 2011
279
20

Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
Mary Beth Terry, Mary B Daly, Kelly Anne Phillips, Xinran Ma, Nur Zeinomar, Nicole Leoce, Gillian S Dite, Robert J MacInnis, Wendy K Chung, Julia A Knight,[...]. J Natl Cancer Inst 2019
24
20

Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study.
James W Jakub, Anne Warren Peled, Richard J Gray, Rachel A Greenup, John V Kiluk, Virgilio Sacchini, Sarah A McLaughlin, Julia C Tchou, Robert A Vierkant, Amy C Degnim,[...]. JAMA Surg 2018
76
20

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
Amy P M Finch, Jan Lubinski, Pål Møller, Christian F Singer, Beth Karlan, Leigha Senter, Barry Rosen, Lovise Maehle, Parviz Ghadirian, Cezary Cybulski,[...]. J Clin Oncol 2014
369
20

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
Tomasz Byrski, Jacek Gronwald, Tomasz Huzarski, Ewa Grzybowska, Magdalena Budryk, Malgorzata Stawicka, Tomasz Mierzwa, Marek Szwiec, Rafal Wisniowski, Monika Siolek,[...]. J Clin Oncol 2010
385
20

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
Kelly Metcalfe, Andrea Eisen, Leigha Senter, Susan Armel, Louise Bordeleau, Wendy S Meschino, Tuya Pal, Henry T Lynch, Nadine M Tung, Ava Kwong,[...]. Br J Cancer 2019
56
20

Identification of the breast cancer susceptibility gene BRCA2.
R Wooster, G Bignell, J Lancaster, S Swift, S Seal, J Mangion, N Collins, S Gregory, C Gumbs, G Micklem. Nature 1995
20

Overview of the main outcomes in breast-cancer prevention trials.
J Cuzick, T Powles, U Veronesi, J Forbes, R Edwards, S Ashley, P Boyle. Lancet 2003
655
13

Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.
Trevor J Powles, Susan J Diem, Carol J Fabian, Patrick Neven, D Lawrence Wickerham, David A Cox, David Muram, Donato Agnusdei, Sherie A Dowsett, Messan Amewou-Atisso,[...]. Breast Cancer Res Treat 2012
33
13

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.
Andrea Decensi, Chris Robertson, Giuseppe Viale, Francesca Pigatto, Harriet Johansson, Elton R Kisanga, Paolo Veronesi, Rosalba Torrisi, Massimiliano Cazzaniga, Serena Mora,[...]. J Natl Cancer Inst 2003
158
13

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Silvana Martino, Jane A Cauley, Elizabeth Barrett-Connor, Trevor J Powles, John Mershon, Damon Disch, Roberta J Secrest, Steven R Cummings. J Natl Cancer Inst 2004
441
13

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Trevor J Powles, Sue Ashley, Alwynne Tidy, Ian E Smith, Mitch Dowsett. J Natl Cancer Inst 2007
270
13


Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Umberto Veronesi, Patrick Maisonneuve, Nicole Rotmensz, Bernardo Bonanni, Peter Boyle, Giuseppe Viale, Alberto Costa, Virgilio Sacchini, Roberto Travaglini, Giuseppe D'Aiuto,[...]. J Natl Cancer Inst 2007
150
13

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.
T Powles, R Eeles, S Ashley, D Easton, J Chang, M Dowsett, A Tidy, J Viggers, J Davey. Lancet 1998
640
13

Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
Andrea Z LaCroix, Trevor Powles, C Kent Osborne, Kevin Wolter, John R Thompson, David D Thompson, D Craig Allred, Róisín Armstrong, Steve R Cummings, Richard Eastell,[...]. J Natl Cancer Inst 2010
85
13

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
532
13

BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.
Gemma Molyneux, Felipe C Geyer, Fiona-Ann Magnay, Afshan McCarthy, Howard Kendrick, Rachael Natrajan, Alan Mackay, Anita Grigoriadis, Andrew Tutt, Alan Ashworth,[...]. Cell Stem Cell 2010
493
13

Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Theresa Wagner, Henry T Lynch, Judy E Garber, Mary B Daly, Claudine Isaacs, Olufunmilayo I Olopade, Susan L Neuhausen, Laura van 't Veer,[...]. J Clin Oncol 2005
272
13

BRCA1 haploinsufficiency for replication stress suppression in primary cells.
Shailja Pathania, Sangeeta Bade, Morwenna Le Guillou, Karly Burke, Rachel Reed, Christian Bowman-Colin, Ying Su, David T Ting, Kornelia Polyak, Andrea L Richardson,[...]. Nat Commun 2014
102
13

Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.
Joanne Kotsopoulos, Jan Lubinski, Pal Moller, Henry T Lynch, Christian F Singer, Charis Eng, Susan L Neuhausen, Beth Karlan, Charmaine Kim-Sing, Tomasz Huzarski,[...]. Breast Cancer Res Treat 2014
41
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.